Zai Lab Limited announced that the 2023 National Reimbursement Drug List (NRDL) released by China?s National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: VYVGART® (efgartigimod alfa injection) is included for the first time in the NRDL for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive; NUZYRA® (omadacycline) is included for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI); and ZEJULA® (niraparib) is renewed for the maintenance treatment of adult patients with platinum-sensitive, first-line and recurrent ovarian cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.78 USD | -2.25% | -0.78% | -34.94% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.94% | 1.76B | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- ZLAB Stock
- News Zai Lab Limited
- Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List